TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

13% of TAVR patients develop acute kidney injury, increasing their risk of in-hospital mortality

Chronic kidney disease, congestive heart failure and liver disease are just some of the comorbidities associated with a greater risk of AKI. 

May 26, 2021
IVUS guidance during DES implantation boosts long-term outcomes in new study

STEMI following TAVR associated with high rates of mortality, PCI failure

The analysis, published in the Journal of the American College of Cardiology, found that post-TAVR STEMI might be rare, but it can lead to substantial complications. 

May 24, 2021
elderly patient mask covid

Apixaban appears safe for most TAVR patients, but questions remain

Researchers tracked data from more than 1,500 patients who underwent a successful TAVR procedure from 2016 to 2019. 

May 18, 2021
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

May 18, 2021
approved approval

Abbott’s new self-expanding TAVR system gains CE mark approval

The solution has still only been approved in the United States for investigational use. 

May 17, 2021
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

BASILICIA before TAVR is safe and effective, new data confirms

Researchers found that the procedure was associated with a high success rate and low mortality and stroke rates after 30 days.

May 11, 2021

AI model helps clinicians predict post-TAVR infective endocarditis

To build and validate their advanced AI model, researchers explored data from nearly 78,000 TAVR hospitalizations.

May 10, 2021
quality imaging appropriateness clinical decision support CAS AUC

11% of TAVR sites deliver below-average care, suggesting a ‘meaningful performance gap’

The study’s authors developed and validated a new performance measure for TAVR care using data from more than 52,000 patients. They shared their full analysis ahead of print in Circulation.

May 7, 2021